Redeye comments on W5 Solutions Q4-results which were below our estimates.
Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CV...
Zoomability Int AB publicerade den 21 februari 2024 bolagets delårsrapport för årets fjärde kvartal.
Redeye provides its initial comments on the Q4 2023 report from Fragbite.
Adj. EBIT SEK -15m (ABGSCe -11m, cons -6m) Strong performance in Rudd: adj.
Artscape and Borosan temporary margin dampeners We forecast 10% EBITA growth in '24e Accumulated FCF...
Atria reported Q4 EBIT of EUR 9.4m, 43% (EUR 7.1m) below LSEG Data & Analytics consensus.
Delivering on FY guidance, Q4 EBITA +21% y-o-y and +15% vs cons North America & RoW better, Europe w...
With the SEK 74 m (estimated 61m net) proceeds from the rights issue, we now look forward to the upd...
Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-...
Redeye update its view on InDex following the year-end report and with the current circumstances we ...
Egetis’ Q4 report presented SEK32.6m in revenues, of which SEK14.
Redeye updates on Raketech following the company’s Q4-results which were largely in line with our ex...
EBITDA and FCF surprised positively in Q4 Much better profitability in '24e-'26e offsets weaker grow...
12% organic sales growth y-o-y Opex increase and IAC affect Q4 Profitability assumptions down on sli...
Sales SEK 7.6m (12.2m), adj. EBIT SEK -18.0m (-8.6m) Several strategic agreements signed, investing ...
År 2023 var ett omställningsår för SDS (”Seamless Distribution Systems” eller ”Bolaget”) där Bolaget...
Syncro Group har publicerat bolagets delårsrapport för det fjärde kvartalet 2023.
Spelbolaget avslutar året med ytterligare ett starkt kvartal och trading update indikerar en bra sta...
CAG uppvisar betydligt mer stabilitet än sina branschkollegor Generellt har 2023 varit ett utmanande...
